StockWireNews

Full Friday AM Update: Key Details On Nasdaq Profile (MYNZ)

March 3rd

Greetings Readers,

MYNZ needs be at the top of your watch-list today.

MYNZ is a low float Nasdaq idea trading towards the lower end of its 52-week range which means there is a ton of upside potential towards previous highs.

And with a 52-week high over $17.00 and an average price target of $18.00, MYNZ could be extremely undervalued at the moment.

Now, I'm not saying that MYNZ is going to surge to either level near term, but the potential needs to be noted.

It also needs to be noted that MYNZ has a 9-Day Raw Stochastic of 21.10% and a 9-Day Williams %R of 88.90%.

Both of those technical indicators could be nearing bounce/reversal territory. And obviously, with that previous 52-week high and an $18 average target, a bounce/reversal could have serious implications.

Take a moment now to look through my initial report below. Then get MYNZ at the top of your watch-list this second.

-----

We've got a ton to go over, so dig in. This is going to take a minute.

When I delivered this past champ to your inboxes originally, it went absolutely bonkers.

Running an insane 200+% (approx.) in the short term, it turned into a stunning multi-dollar mover.

With its breakout potential starting to grow again, I brought it back to attention only to watch it pop another 30+% in a very little period of time.

And most recently when I brought it to your attention on December 5th after it closed at $7.80, it made a $1.00+ (14%) approximate move to a high of $8.95 the next day.

So when I saw it had 2 press releases out this week, a low float of fewer than 11Mn shares, an average analyst price target of $18.00, and key IP acquisition news in 2023, I realized it needed to be back on alert immediately.

For Thursday, March 2nd, there is only one Nasdaq profile to have on your watch-list:

*Mainz Biomed B.V. (MYNZ)*

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.

And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know:

No. 1 - Low Float Volatility Could Be On Display Daily

No. 2 - Two Different Analysts Provide An Average Price Target Of $18

No. 3 - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone

No. 4 - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK)

No. 5 - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead

But more on those in a second...

About MYNZ: Early Identification Of Cancer Saves Lives

Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.

Developing market-ready molecular in-vitro diagnostics tests since 2010.

Their goal is to place effective solutions where they need to be… In your hands.

A Blockbuster Early Detection Test for Colorectal Cancer

Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.

Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022.

U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year.

Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.

Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.

Attractive Valuation: They believe their current valuation holds tremendous upside.

ColoAlert - Simple, Fast, Accurate and Non-Invasive

• A PCR-based CRC early detection stool test
• Non-invasive, no preparation or sedation, no time off work
• 98% patient satisfaction – Easy product to use
• Designed to offer affordable CRC screening solutions

Grab more key details and sources here.

-----

Mentioned above, MYNZ has 5 potential catalysts that could provide it with a near term breakout spark. Check them out:

No. 1 MYNZ Potential Catalyst - Low Float Volatility Could Be On Display Daily

According to the Yahoo Finance website, MYNZ has a low float.

The website reports this profile to have approximately 10.56Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2023 positive company news help provide a near term spark?

-----

No. 2 MYNZ Potential Catalyst - Two Different Analysts Provide An Average Price Target Of $18

Wow. Over at TipRanks, I found this:

From Wednesday's closing valuation, MYNZ is displaying a ton of potential upside to this $18 average target.

In fact, that's over 125+% potential upside.

Now, I'm not saying this profile is going to surge to $18 this week, but the potential needs to be noted.

And with a 52-week high of $17.81, that price target might not be all that far-fetched.

-----

No. 3 MYNZ Potential Catalyst - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone

Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property (“IP”) for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorectal cancer (“CRC”) being commercialized across Europe. Simultaneously, the Company also exercised its exclusive option with SOCPRA Sciences Sante et Humaines S.E.C. (“SOCPRA”), to outright purchase IP, including a pending patent, associated with a portfolio of novel gene expression (mRNA) biomarkers that have demonstrated ability to detect CRC lesions, including advanced adenomas (“AA”), a type of pre-cancerous polyp often attributed to this deadly disease.

“This is an important value generation milestone for us as we continue executing our commercial strategy and product development plan to ultimately bring to market the gold-standard CRC self-administered diagnostic test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Securing complete IP ownership is integral to our growth strategy as it streamlines administration, reduces per-test expenses, and provides us the opportunity to ramp-up corporate development activities,” added Baechler.

...

Read the full article here.

-----

No. 4 MYNZ Potential Catalyst - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK)

Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK

Continued roll-out in Europe with onboarding of new lab partners

BERKELEY, Calif. and MAINZ, Germany, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the establishment of commercial partnerships for ColoAlert with Marylebone Laboratory (Marylebone Lab LTD) and Instituto de Microecologia, two leading independent laboratories covering England and Spain. ColoAlert, Mainz Biomed’s flagship product, a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC), is currently being commercialized across Europe and in select international markets via a differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

...

Read the full article here.

-----

No. 5 MYNZ Potential Catalyst - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead

Mainz Biomed Provides Year-End 2022 Corporate Review

BERKELEY, US and MAINZ, Germany , Jan. 03, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a corporate summary for the fiscal year ended December 31, 2022.

Key Commercial, Operational and Product Development Highlights

• Launched U.S.-based eAArly DETECT study by enrolling the first patient; study focused on the performance of Mainz Biomed’s mRNA biomarkers in identifying Advance Adenomas (AA), a type of pre-cancerous polyp often attributed to colorectal cancer (CRC); on track to report results in 1H 2023.
• Initiated ReconAAsense, U.S. Pivotal Clinical Study with Company’s CRC screening test; anticipate commencing patient enrollment in mid-2023.
• Continued executing differentiated business model of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
• Ramped up international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for CRC, including five new lab partners in Germany and Italy.
• Enhanced leadership team with appointments to Board of Directors and Company executives to lead commercial and product development groups, with former executives and senior management from Roche, Abbott, Luminex, and Qiagen; expanded Medical Advisory Board of global leaders in molecular diagnostic development.
• Initiated and commenced patient enrollment in ColoFuture, a European study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert; potential to identify advanced adenomas, a type of pre-cancerous polyp often attributed to CRC; with results expected in 2023.
• Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer.
• Acquired a portfolio of novel mRNA biomarkers to upgrade ColoAlert’s technical profile to achieve “gold standard” status for AA and CRC at-home testing.
• Executed a USD 25.8Mn (gross) public follow-on offering.

“The past year has proven to be an extraordinary period of growth as we strengthened every aspect of the Company while expanding our international commercial footprint and executing our product development programs,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We head into 2023 with a great deal of momentum, and on behalf of the management team and Board of Directors, I wish to extend gratitude to our shareholders for their support as we continue our journey to become a leading provider of cancer-focused early detection and disease prevention molecular diagnostics.”

...

Read the full article here.

-----

MYNZ Recap - 5 Must-Know Potential Catalyst For This Nasdaq Past Champ

No. 1 - Low Float Volatility Could Be On Display Daily

No. 2 - Two Different Analysts Provide An Average Price Target Of $18

No. 3 - Acquisition Of IP Portfolio Could Act As An Important Value Generation Milestone

No. 4 - MYNZ Adds To European Network Of Lab Partners (Enters Markets In Spain & UK)

No. 5 - 2022 Company Highlights Provide Key Insights Of A Potentially Transformative Year Ahead

-----

Coverage is officially reinitiated on MYNZ. When time permits, do this:

Get MYNZ on your radar now.

Sincerely,

Kai Parker

StockWireNews

(Always Remember The Stock Prices Could Be Significantly Lower Now From The Dates I Provided.)